Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Barclays PLC grew its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 273.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,463 shares of the company's stock after acquiring an additional 12,051 shares during the quarter. Barclays PLC owned 0.06% of LENZ Therapeutics worth $391,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. Parkman Healthcare Partners LLC acquired a new position in shares of LENZ Therapeutics in the 3rd quarter worth approximately $3,308,000. The Manufacturers Life Insurance Company acquired a new position in LENZ Therapeutics during the third quarter worth $743,000. Bank of New York Mellon Corp lifted its holdings in shares of LENZ Therapeutics by 255.4% during the second quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company's stock valued at $687,000 after acquiring an additional 28,556 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of LENZ Therapeutics by 197.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock valued at $2,929,000 after acquiring an additional 81,901 shares during the period. Finally, State Street Corp boosted its stake in shares of LENZ Therapeutics by 18.7% in the 3rd quarter. State Street Corp now owns 289,154 shares of the company's stock valued at $6,865,000 after purchasing an additional 45,600 shares in the last quarter. Institutional investors and hedge funds own 54.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LENZ shares. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Raymond James initiated coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an "outperform" rating and a $37.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $35.40.

LENZ Therapeutics Stock Performance

NASDAQ LENZ traded up $0.10 during trading hours on Friday, hitting $22.50. 143,402 shares of the company traded hands, compared to its average volume of 153,115. LENZ Therapeutics, Inc. has a twelve month low of $14.42 and a twelve month high of $38.93. The business's 50-day moving average is $31.50 and its 200-day moving average is $26.40.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.09. During the same quarter last year, the company earned ($1.33) EPS. Analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.